Research programme: musculoskeletal therapeutics - AblynxAlternative Names: Nanobodies - Ablynx
Latest Information Update: 23 Sep 2009
At a glance
- Originator Ablynx; Procter & Gamble
- Developer Ablynx
- Mechanism of Action G protein-coupled receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Musculoskeletal disorders
- Discontinued Metabolic disorders